iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021
November 03 2021 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced that it will host a
conference call and live webcast at 4:30 p.m. ET on Wednesday,
November 10, 2021 to report its third quarter 2021 financial
results and provide a corporate update.
To access the live conference call, please dial 833-927-1758
(domestic) or 929-526-1599 (international) and refer to conference
access code 861337. A live audio webcast of the event will also be
accessible from the News and Events page of the Company’s website
at https://investors.iteostherapeutics.com/news-and-events/events.
The archived webcast will be available approximately two hours
after the completion of the event and for one week following the
call.
To pre-register for the event, please use the following link to
receive access details via
email:https://www.incommglobalevents.com/registration/q4inc/9144/iteos-therapeutics-q3-2021-earnings-conference-call/.
About iTeos Therapeutics, Inc.iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of cancer
immunology and immunosuppressive pathways to design novel product
candidates with the potential to fully restore the immune response
against cancer. The Company’s innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes. The first antibody product candidate,
EOS-448, is a high affinity, potent, anti-TIGIT antibody with a
functional Fc domain, designed to enhance the anti-tumor response
through a multifaceted immune modulatory mechanism, currently
progressing in multiple indications in collaboration with GSK. The
Company is also advancing inupadenant, a next-generation adenosine
A2A receptor antagonist tailored to overcome cancer
immunosuppression into proof-of concept trials in several
indications following encouraging single-agent activity in Phase 1.
iTeos Therapeutics is headquartered in Cambridge, MA with a
research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:Ryan Baker iTeos Therapeutics,
Inc. Ryan.Baker@iteostherapeutics.com
Media Contact:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2023 to Sep 2024